(2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide
C16H21N7O — CID 91800662
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide
(2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide (PubChem CID 91800662) has the molecular formula C16H21N7O and a molecular weight of 327.39 g/mol. Its IUPAC name is (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide.
Molecular Properties
| Compound Name | (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide |
|---|---|
| PubChem CID | 91800662 |
| Molecular Formula | C16H21N7O |
| Molecular Weight | 327.39 g/mol |
| Exact Mass | 327.18 |
| IUPAC Name | (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl]pyrrolidine-2-carboxamide |
| SMILES | Cc1cc(Nc2cc(C3CC3)[nH]n2)nc(N2CCC[C@H]2C(N)=O)n1 |
| InChI | InChI=1S/C16H21N7O/c1-9-7-13(19-14-8-11(21-22-14)10-4-5-10)20-16(18-9)23-6-2-3-12(23)15(17)24/h7-8,10,12H,2-6H2,1H3,(H2,17,24)(H2,18,19,20,21,22)/t12-/m0/s1 |
| InChIKey | DIWTWVAPZNCJHQ-LBPRGKRZSA-N |
| XLogP | 1.58 |
| TPSA | 112.82 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 24 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 327.39 |
| LogP ≤ 5 | 1.58 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 91800662 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.